New combo could make stem cell transplants safer and more effective
NCT ID NCT07214064
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 42 times
Summary
This study tests whether adding the drug venetoclax to the usual pre-transplant chemotherapy can help people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) without causing more harm. About 27 adults aged 18–75 will receive this new combination before a donor stem cell transplant. The main goal is to see if more patients survive at least 28 days after the transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital , Department of Internal Medicine II
Tübingen, Baden-Wurttemberg, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.